Investors tracking the intersection of artificial intelligence and biotechnology frequently encounter two high-volatility names: Ginkgo Bioworks (DNA) and Recursion Pharmaceuticals (RXRX). Both companies market themselves around AI-driven approaches to biology, yet their business models, revenue profiles, and near-term catalysts differ meaningfully. This stock comparison is most relevant for growth-oriented and thematic investors willing to accept elevated risk in exchange for exposure to emerging life-sciences technology. By examining relative performance, market positioning, and recent developments, traders can better assess which of these two names offers a more compelling risk-reward profile in the current environment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Ginkgo Bioworks (DNA) is a cell-engineering and lab-automation company that has undergone a significant strategic transformation. After divesting its biosecurity business, the company has refocused on two offerings built on one autonomous lab platform: Autonomous Labs, where it sells robotic laboratory hardware, and Cloud Lab, where it runs experiments for customers at its Nebula facility. In recent weeks, this pivot produced a notable milestone—its first autonomous lab sale to a top-tier pharmaceutical company, Novo Nordisk—alongside new government-related programs and a growing base of biopharma and AI-lab customers.
Financially, Ginkgo's third-quarter revenue of roughly $27.7 million declined about 6% year over year, though it beat analyst expectations, and the net loss narrowed as cost-cutting took hold. The company reported approximately $285 million in cash and no bank debt. Despite these improvements, shares remain highly volatile, and Wall Street's consensus rating sits at Moderate Sell, reflecting continued questions about revenue growth and the path to profitability. From what I see, the hardware pivot is promising but still needs to show clearer traction.
Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company that integrates biology, chemistry, automation, and data science to industrialize AI-driven drug discovery. It has no approved commercial products and generates revenue primarily through collaborations and milestone payments with partners such as Sanofi, Roche/Genentech, and Takeda. Recent market activity has been shaped by a positive readout from the TUPELO study of its REC-4881 candidate, early partial responses for REC-1245, and a $10 million milestone payment triggered when Sanofi optioned a drug candidate.
In its most recent quarter, revenue surged to about $18.55 million—a gain of roughly 258% year over year—while the net loss narrowed. The company highlighted a cash runway extending toward 2029, and Wall Street's consensus rating is Moderate Buy. However, the shares have also shown notable volatility, and the company's milestone-dependent revenue model and elevated cash burn remain key considerations for investors. I’m watching this closely as the clinical data continues to develop.
The core contrast between these two stocks is business model maturity and revenue visibility. DNA is transitioning toward selling and operating laboratory infrastructure—a hardware-plus-services model—while RXRX remains squarely in clinical-stage drug development, where revenue is milestone-driven and binary by nature. Both depend heavily on large pharmaceutical partnerships, but RXRX has a deeper roster of named collaborators and a more established pipeline of clinical data.
On momentum and sentiment, the two have recently diverged. RXRX enjoys a Moderate Buy consensus and improving revenue trends, whereas DNA faces a Moderate Sell consensus amid year-over-year revenue declines. Risk profiles also differ: DNA has been among the most volatile U.S. stocks, while RXRX carries clinical, execution, and dilution risks tied to its financing needs.
Weighing trend consistency, stability, catalyst breadth, and relative market positioning, Tickeron's AI currently favors RXRX over DNA. The preference is driven by RXRX's stronger analyst sentiment, expanding collaboration milestones, improving revenue trajectory, and a comparatively more constructive risk-reward setup. By contrast, DNA's strategic pivot is promising but still translating into declining revenue and elevated price volatility. This is a probabilistic assessment based on observable factors rather than a definitive forecast, and the relative standing of the two names could shift as new data and catalysts emerge.
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and universe of securities. Because no single approach suits every market regime, only the strongest and most condition-appropriate bots earn a place in the curated Trending AI Robots section. This page highlights automated strategies currently demonstrating compelling alignment with market conditions, giving users a focused starting point rather than an overwhelming list. The bots vary widely—from short-term momentum strategies to longer-horizon trend-following systems—so traders can compare their approaches and statistics side by side. Exploring the Trending AI Robots page can help investors see how algorithmic tools are positioning across names like DNA and RXRX. In my view, this resource adds a practical layer when evaluating names in fast-moving sectors.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
The RSI Indicator for RXRX moved into overbought territory on November 17, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 208 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
RXRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RXRX as a result. In 81 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for RXRX turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 43 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
RXRX moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RXRX crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for RXRX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.063) is normal, around the industry mean (3.592). P/E Ratio (-3.520) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. RXRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology